Smartwatch study aims to Fine-Tune Parkinson's medication timing

NCT ID NCT07138560

Recruiting now Disease control Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether a wrist-worn sensor (KinesiaU) can accurately measure how long people with Parkinson's disease experience 'good on-time' — periods when medication works well and symptoms are controlled without troublesome movements. Researchers are testing IPX-203 (Crexont), an extended-release levodopa, in 22 adults aged 40 and older with Parkinson's. The goal is to see if the sensor can help doctors adjust dosing schedules for better symptom management in daily life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPX-203 (Crexont ER, an extended-release levodopa formulation)
What this could lead to: If successful, this study could show that wearable sensors help doctors fine-tune Parkinson's medication dosing for better symptom control throughout the day.
What could go wrong: This is a small, early-phase study with only 22 participants, so results may not apply to everyone. The wearable device may not capture all symptom changes accurately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.